<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00349531</url>
  </required_header>
  <id_info>
    <org_study_id>248.615</org_study_id>
    <nct_id>NCT00349531</nct_id>
  </id_info>
  <brief_title>A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS</brief_title>
  <official_title>A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/Day Per os for 12 Weeks to Investigate the Effects on RLS Symptoms (IRLS) and Sleep Disturbance (MOS Sleep Scale) in Out-patients With Idiopathic Restless Legs Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the effects on RLS symptoms and sleep
      disturbance of pramipexole (Mirapexin) 0.125 mg/day to 0.75 mg/day per os for 12 weeks,
      compared to placebo, in the treatment of patients with idiopathic Restless Legs Syndrome
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint: change from baseline after 12 weeks in IRLS total score. Co-primary endpoint: change from baseline after 12 weeks in MOS sleep disturbance score.</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints: CGI-I and IRLS responder rate other MOS dimensions, RLS-6 items 4-6, IRLS item 10, VAS ,Verbal Fluency Tests ,RLS-QoL scores PGI responder rate adverse event profile, systolic and diastolic blood pressure, pulse rate</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">369</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent consistent with ICH-GCP and local IRB/IEC requirements
             obtained prior to any study procedures being performed and the ability and willingness
             to comply with study treatment regimen and to attend study assessments.

          2. Male or female out-patients aged 18-80 years.

          3. Diagnosis of idiopathic RLS according to the clinical RLS criteria of the IRLSSG
             [P03-03355]. All four criteria must be present to fulfil the diagnosis of RLS:

               -  An urge to move the legs, usually accompanied or caused by uncomfortable and
                  unpleasant sensations in the legs. (Sometimes the urge to move is present without
                  the uncomfortable sensations and sometimes the arms or other body parts are
                  involved in addition to the legs)

               -  The urge to move or unpleasant sensations begin or worsen during periods of rest
                  or inactivity such as lying or sitting

               -  The urge to move or unpleasant sensations are partially or totally relieved by
                  movement, such as walking or stretching, at least as long as the activity
                  continues

               -  The urge to move or unpleasant sensations are worse in the evening or night than
                  during the day or only occur in the evening or night. (When symptoms are very
                  severe, the worsening at night may not be noticeable but must have been
                  previously present).

          4. RLS symptoms present at least 2 to 3 days per week during the last 3 months prior to
             baseline (Visit 2).

          5. IRLS total score &gt;15 at baseline (Visit 2).

        Exclusion Criteria:

          1. Women of child-bearing potential who do not use during the trial an adequate method of
             contraception.

          2. Women of child-bearing potential not having negative pregnancy test at screening.

          3. Breastfeeding women.

          4. Concomitant or previous pharmacologic therapy for RLS with: dopamine agonists or
             levodopa (within 14 days prior to baseline), levodopa with augmentation, unsuccessful
             prior treatment with non-ergot dopamine agonists.

          5. All treatment less than 14 days or concomitant treatment with medication or dietary
             supplements which could significantly influence RLS symptoms.

          6. Withdrawal symptoms.

          7. Pramipexole non-responders in other indications than RLS.

          8. Patients with known hypersensitivity to pramipexole or any other component of the
             investigational product or placebo tablets.

          9. Diabetes mellitus requiring insulin therapy.

         10. Any of the following laboratory results at screening:

               -  any clinically significant abnormalities in laboratory parameters;

               -  haemoglobin below LLN.

         11. Clinically significant renal disease or calculated creatinine clearance lower than 30
             mL/minute.

         12. Clinically significant hepatic disease or GPT &gt;2 times the ULN.

         13. Serum ferritin &lt;10 ng/mL.

         14. History of/or malignant melanoma.

         15. History of/or clinically significant vision abnormalities.

         16. History of/or any other sleep disorder (other than RLS-related).

         17. History of/or major depressive disorder or any psychotic disorder, mental disorders or
             any present Axis I psychiatric disorder according to DSM IV requiring any medical
             therapy.

         18. History of/or clinical signs of suicidal behaviour, suicide ideation or acute suicidal
             tendency according to the investigator's opinion.

         19. History of/or alcohol abuse or drug addiction (within 2 years).

         20. Patients on a shift-work-schedule or who are otherwise unable to follow a regular
             sleep-wake cycle.

         21. Participation in an investigational drug study within one month.

         22. Any clinically significant conditions that would interfere or constitute a health
             hazard for the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>248.615.45103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kgs. Lyngby</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.45102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København K</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.45101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.45104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vaerløse</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.35101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.35104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joensuu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.35103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.35102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin-Steglitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Görlitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hattingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.35302</name>
      <address>
        <city>BIrr</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.35301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Carrigtwohill</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.35303</name>
      <address>
        <city>Castlecomer</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.39007 Policlinico di Bari - Università di Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.39006 Ospedale Civile di Dolo</name>
      <address>
        <city>Dolo (VE)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.39002 Ospedale S. Martino - A. O. Università di Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.39008 Policlinico Gaetano Martino</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.39001 Istituto San Raffaele Turro</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.39004 IRCCS Fondazione Istituto Neurologico &quot;C. Mondino&quot;</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.39005 Ospedale S. Chiara</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.39003 A. O. Santa Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.47101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bekkestua</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.47102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fevik</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.47104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moelv</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.47103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.47105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tvedestrand</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.3408 Hospital Nuestra Señora de Sonsoles</name>
      <address>
        <city>Avila</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.3402</name>
      <address>
        <city>Maderid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.3404 Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.3406</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.3407</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.3403 Hospital General de Catalunya</name>
      <address>
        <city>San Cugat del Valles (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.46101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.46103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.46102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hedemora</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.46104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Buckshaw Village, Chorley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.44004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.44009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Romford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Green, Crawley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2006</study_first_submitted>
  <study_first_submitted_qc>July 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2006</study_first_posted>
  <last_update_submitted>May 18, 2012</last_update_submitted>
  <last_update_submitted_qc>May 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2012</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

